Effective Feb. 23, 2024, the company's prospectus supplement dated Feb. 23, 2024, to the short form base shelf prospectus dated March 31, 2023, was filed with and accepted by the TSX Venture Exchange.

The exchange has been advised that closing occurred on Feb. 29, 2024, for gross proceeds of $34.5-million (including the exercise of the overallotment option).

Underwriters:  PI Financial Corp. (the lead underwriter), and Canaccord Genuity Corp., CIBC World Markets Inc., Raymond James Ltd., Stifel Nicolaus Canada Inc. and BMO Nesbitt Burns Inc.

Offering:  23 million common shares of the company (including those shares issued pursuant to the exercise of the overallotment option)

Share price:  $1.50 per share

Underwriters' commissions:  an aggregate cash payment of $2.07-million, being equal to 6 per cent of the gross proceeds of the supplement offering; 1.38 million non-transferable compensation warrants issued to the underwriters and may be exercised into shares at a price of $1.50 per share at any time prior to Feb. 28, 2026

Overallotment option:  The company granted to the underwriters an option to purchase additional shares of up to 15 per cent of the offering. The overallotment option was exercised in full at closing, equal to three million shares at $1.50 per share.

Please refer to the company's news releases dated Feb. 21, 2024, and Feb. 29, 2024, for further details.